B. Riley Has Optimistic Outlook of CRBP FY2025 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) – Equities research analysts at B. Riley raised their FY2025 earnings estimates for shares of Corbus Pharmaceuticals in a report released on Thursday, March 13th. B. Riley analyst K. Patel now forecasts that the biopharmaceutical company will post earnings of ($3.70) per share for the year, up from their previous forecast of ($5.60). The consensus estimate for Corbus Pharmaceuticals’ current full-year earnings is ($4.23) per share. B. Riley also issued estimates for Corbus Pharmaceuticals’ Q4 2025 earnings at ($0.92) EPS, FY2026 earnings at ($3.14) EPS and FY2027 earnings at ($3.27) EPS.

A number of other brokerages have also recently issued reports on CRBP. HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price (down from $75.00) on shares of Corbus Pharmaceuticals in a report on Wednesday, March 12th. Jefferies Financial Group dropped their target price on shares of Corbus Pharmaceuticals from $70.00 to $53.00 and set a “buy” rating on the stock in a report on Tuesday, March 11th. Piper Sandler initiated coverage on shares of Corbus Pharmaceuticals in a research note on Monday, December 2nd. They issued an “overweight” rating and a $35.00 price target on the stock. Wedbush reiterated an “outperform” rating and issued a $51.00 price target on shares of Corbus Pharmaceuticals in a research note on Wednesday, March 12th. Finally, William Blair initiated coverage on shares of Corbus Pharmaceuticals in a research note on Friday, February 28th. They issued an “outperform” rating on the stock. One research analyst has rated the stock with a sell rating, nine have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $59.13.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP stock opened at $6.33 on Monday. The firm’s 50-day moving average is $9.19 and its 200-day moving average is $17.71. The stock has a market cap of $77.43 million, a price-to-earnings ratio of -1.35 and a beta of 2.63. Corbus Pharmaceuticals has a 52-week low of $6.26 and a 52-week high of $61.90.

Corbus Pharmaceuticals (NASDAQ:CRBP) last issued its earnings results on Tuesday, March 11th. The biopharmaceutical company reported ($0.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.24.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently made changes to their positions in CRBP. Millennium Management LLC grew its position in shares of Corbus Pharmaceuticals by 215.0% during the 4th quarter. Millennium Management LLC now owns 386,653 shares of the biopharmaceutical company’s stock worth $4,563,000 after purchasing an additional 263,902 shares in the last quarter. Orbimed Advisors LLC raised its stake in shares of Corbus Pharmaceuticals by 28.5% during the fourth quarter. Orbimed Advisors LLC now owns 1,172,287 shares of the biopharmaceutical company’s stock valued at $13,833,000 after acquiring an additional 259,735 shares during the last quarter. Altium Capital Management LLC raised its stake in shares of Corbus Pharmaceuticals by 97.4% during the fourth quarter. Altium Capital Management LLC now owns 385,000 shares of the biopharmaceutical company’s stock valued at $4,543,000 after acquiring an additional 190,000 shares during the last quarter. State Street Corp raised its stake in shares of Corbus Pharmaceuticals by 34.6% during the third quarter. State Street Corp now owns 595,576 shares of the biopharmaceutical company’s stock valued at $12,287,000 after acquiring an additional 153,243 shares during the last quarter. Finally, Prosight Management LP increased its position in shares of Corbus Pharmaceuticals by 107.7% during the fourth quarter. Prosight Management LP now owns 270,000 shares of the biopharmaceutical company’s stock worth $3,186,000 after buying an additional 140,000 shares during the period. Institutional investors and hedge funds own 64.64% of the company’s stock.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc, a biopharmaceutical company, develops products to defeat serious illness. It develops CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E (MMAE), which is in Phase I clinical trial; CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells for the treatment of solid tumors; CRB-913, a peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity.